Wegovy week 9: the decision point most people don't expect

The dose decision sitting in front of you at week 9

The semaglutide titration ladder (0.25 mg, then 0.5 mg, then 1.0 mg, 1.7 mg, and finally 2.4 mg) is paced at roughly four-week intervals, though your prescriber may extend any phase if side effects make moving up uncomfortable. Week 9 means you have probably completed two full months on Wegovy and are nearing the point where 1.0 mg becomes the next clinical question.

This is a genuine decision, not a formality. Some people sail into the increase with little trouble; others find that 0.5 mg still brings nausea, and their prescriber opts to hold at that level a little longer. Neither path is wrong. The purpose of the graduated schedule is to give your body time to adjust, rushing it does not improve outcomes and often makes side effects harder to manage.

If you are unsure whether your current dose is being tolerated well enough to step up, that conversation belongs with your prescriber. The full Wegovy treatment overview sets out how the titration schedule is designed and what clinical review looks like at each stage.

What the side-effect picture usually looks like nine weeks in

Nausea, indigestion, constipation and loose stools are the most commonly reported effects across the semaglutide clinical programme, as documented by the NHS medicines information for semaglutide. The pattern that emerges with most people is that these effects are sharpest in the first two weeks of each dose phase and then gradually settle. If you want to compare notes on how this phase typically unfolds, our guide to Wegovy week 5 covers what most people experience as the 0.5 mg phase gets under way.

That calm can be temporary. Stepping up to 1.0 mg often brings a short recurrence of nausea and changed bowel habits as the body adjusts to the higher level. Knowing this in advance helps: it does not mean the medicine has stopped suiting you, and it typically resolves within days to two weeks.

One practical note: if you keep your pen in the fridge door rather than the back shelf, it is easier to remember that taking it on the same day each week keeps blood levels stable, inconsistent timing can amplify side effects. For any symptoms that are severe, persistent, or include strong stomach pain spreading to the back, seek medical attention promptly rather than waiting for your next review. The MHRA highlighted persistent severe abdominal pain as a sign to act on without delay.

Our week-by-week Wegovy guide maps the full side-effect trajectory so you can see where week 9 fits in the broader picture.

Reading early weight changes, and resisting the wrong conclusion

Week 9 is close enough to the start of treatment that weight changes are not yet a reliable signal of how well Wegovy will ultimately work for you. The STEP 1 trial (the pivotal study behind Wegovy's licensing) ran for 68 weeks, with participants reaching and sustaining their maintenance dose for the majority of that time before average weight loss of around 15% was recorded. The full STEP 1 trial paper is published in the New England Journal of Medicine for anyone who wants to read the methodology.

At nine weeks, you are still in the titration phase. Some people see meaningful early movement on the scale; others see very little until they reach a higher dose. Both are within the normal range. NICE guidance on semaglutide recommends that the formal assessment of whether treatment is working happens at six months on the highest tolerated dose, not at two months.

What matters more right now: are you eating less without significant distress? Are portions naturally smaller? Is snacking less automatic? These functional signals often precede weight change by several weeks. Tracking them alongside the number on the scale gives a more complete picture of how your body is responding.

If you are considering switching medicine or wondering whether a different GLP-1 might suit you better, our page on semaglutide for weight management covers how it compares to other options, and the weight-loss treatment overview explains the alternatives available through a private prescription.

When the nine-week mark raises bigger questions

Some people arrive at week 9 with questions that go beyond dose timing. They may have missed a dose and feel uncertain about what to do. They may be wondering whether it is safe to travel with the pen, whether their contraception is still effective, or what to do ahead of a planned procedure. These are all real and reasonable concerns. It can also help to look back at what week 6 of Wegovy typically involves and forward to what week 7 usually brings, so you have a clearer sense of the progression leading up to where you are now.

On missed doses: your Patient Information Leaflet gives specific guidance on the window within which a missed dose can be taken; if you are outside that window, your prescriber or the leaflet will tell you to skip it rather than double up. On contraception: if you take the oral contraceptive pill, your prescriber should have discussed adding a barrier method during dose increases, because semaglutide's effect on gastric emptying can affect pill absorption. On surgical procedures: your whole clinical team, including the anaesthetist, needs to know you are on this medicine before any procedure takes place.

None of these questions should wait until side effects become unmanageable. If something feels off or you have a situation not covered in your information pack, reaching out to your aftercare team is exactly the right move. You can also explore our clinical FAQs for answers to questions our prescribers hear regularly. If you are not yet in treatment and are weighing up whether Wegovy is the right route, check your eligibility with our prescribers, there is no obligation and no fee for the consultation.